These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 34254328)

  • 1. "Real-world" effectiveness of methylphenidate in improving the academic achievement of Attention-Deficit Hyperactivity Disorder diagnosed students-A systematic review.
    de Faria JCM; Duarte LJR; Ferreira LA; da Silveira VT; Menezes de Pádua C; Perini E
    J Clin Pharm Ther; 2022 Jan; 47(1):6-23. PubMed ID: 34254328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.
    Storebø OJ; Pedersen N; Ramstad E; Kielsholm ML; Nielsen SS; Krogh HB; Moreira-Maia CR; Magnusson FL; Holmskov M; Gerner T; Skoog M; Rosendal S; Groth C; Gillies D; Buch Rasmussen K; Gauci D; Zwi M; Kirubakaran R; Håkonsen SJ; Aagaard L; Simonsen E; Gluud C
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012069. PubMed ID: 29744873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.
    Goldman LS; Genel M; Bezman RJ; Slanetz PJ
    JAMA; 1998 Apr; 279(14):1100-7. PubMed ID: 9546570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of attention-deficit/hyperactivity disorder.
    Jadad AR; Boyle M; Cunningham C; Kim M; Schachar R
    Evid Rep Technol Assess (Summ); 1999 Nov; (11):i-viii, 1-341. PubMed ID: 10790990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials.
    Storebø OJ; Krogh HB; Ramstad E; Moreira-Maia CR; Holmskov M; Skoog M; Nilausen TD; Magnusson FL; Zwi M; Gillies D; Rosendal S; Groth C; Rasmussen KB; Gauci D; Kirubakaran R; Forsbøl B; Simonsen E; Gluud C
    BMJ; 2015 Nov; 351():h5203. PubMed ID: 26608309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.
    Wigal SB; Wigal T; Schuck S; Brams M; Williamson D; Armstrong RB; Starr HL
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):121-31. PubMed ID: 21488750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mood and Proneness to Boredom Are Associated with Poorer Continuous Performance Test Results, Which May Improve with Methylphenidate Treatment, in Attention-Deficit/Hyperactivity Disorder.
    Golubchik P; Schoen G; Weizman A
    J Child Adolesc Psychopharmacol; 2021 May; 31(4):310-314. PubMed ID: 33956509
    [No Abstract]   [Full Text] [Related]  

  • 9. Methodological advantages and disadvantages of parallel and crossover randomised clinical trials on methylphenidate for attention deficit hyperactivity disorder: a systematic review and meta-analyses.
    Krogh HB; Storebø OJ; Faltinsen E; Todorovac A; Ydedahl-Jensen E; Magnusson FL; Holmskov M; Gerner T; Gluud C; Simonsen E
    BMJ Open; 2019 Mar; 9(3):e026478. PubMed ID: 30928951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
    Rodrigues R; Lai MC; Beswick A; Gorman DA; Anagnostou E; Szatmari P; Anderson KK; Ameis SH
    J Child Psychol Psychiatry; 2021 Jun; 62(6):680-700. PubMed ID: 32845025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies.
    Coghill D; Banaschewski T; Zuddas A; Pelaz A; Gagliano A; Doepfner M
    BMC Psychiatry; 2013 Sep; 13():237. PubMed ID: 24074240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of parental training, methylphenidate treatment, and their combination on academic achievements and behavior at school of children with attention-deficit hyperactivity disorder.
    Golubchik P; Hamerman H; Manor I; Peskin M; Weizman A
    Int Clin Psychopharmacol; 2018 Jul; 33(4):229-232. PubMed ID: 29608460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review.
    Wu EQ; Hodgkins P; Ben-Hamadi R; Setyawan J; Xie J; Sikirica V; Du EX; Yan SY; Erder MH
    CNS Drugs; 2012 Jul; 26(7):581-600. PubMed ID: 22712698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of established and off-label ADHD drug therapies for cognitive impairment or attention-deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force.
    Miskowiak KW; Obel ZK; Guglielmo R; Bonnin CDM; Bowie CR; Balanzá-Martínez V; Burdick KE; Carvalho AF; Dols A; Douglas K; Gallagher P; Kessing LV; Lafer B; Lewandowski KE; López-Jaramillo C; Martinez-Aran A; McIntyre RS; Porter RJ; Purdon SE; Schaffer A; Stokes PRA; Sumiyoshi T; Torres IJ; Van Rheenen TE; Yatham LN; Young AH; Vieta E; Hasler G
    Bipolar Disord; 2024 May; 26(3):216-239. PubMed ID: 38433530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Forty years of methylphenidate treatment in Attention-Deficit/ Hyperactivity Disorder.
    Conners CK
    J Atten Disord; 2002; 6 Suppl 1():S17-30. PubMed ID: 12685516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attention Deficit Hyperactivity Disorder Symptoms and Low Educational Achievement: Evidence Supporting A Causal Hypothesis.
    de Zeeuw EL; van Beijsterveldt CEM; Ehli EA; de Geus EJC; Boomsma DI
    Behav Genet; 2017 May; 47(3):278-289. PubMed ID: 28191586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder.
    Kang KD; Yun SW; Chung U; Kim TH; Park JH; Park IH; Han DH
    Hum Psychopharmacol; 2016 Mar; 31(2):76-82. PubMed ID: 26756111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Storebø OJ; Faltinsen E; Zwi M; Simonsen E; Gluud C
    Clin Pharmacol Ther; 2018 Oct; 104(4):606-609. PubMed ID: 30006934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidelines and algorithms for the use of methylphenidate in children with Attention-Deficit/ Hyperactivity Disorder.
    Greenhill L; Beyer DH; Finkleson J; Shaffer D; Biederman J; Conners CK; Gillberg C; Huss M; Jensen P; Kennedy JL; Klein R; Rapoport J; Sagvolden T; Spencer T; Swanson JM; Volkow N
    J Atten Disord; 2002; 6 Suppl 1():S89-100. PubMed ID: 12685523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.